Understanding and controlling chronic immune activation in the HIV-infected patients suppressed on combination antiretroviral therapy

Current HIV/AIDS Reports

Volumn 10, Issue 1, 2013, Pages 21-32

  Taiwo, Babafemi ^a   Barcena, Luis ^a   Tressler, Randall ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Chronic immune activation; Co infections; Combination antiretroviral therapy (cART); HIV; HIV pathogenesis and treatment; Immune activation; Microbial translocation

Indexed keywords

ACETYLSALICYLIC ACID; ACICLOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATORVASTATIN; CD14 ANTIGEN; CHLOROQUINE; EMTRICITABINE; GANCICLOVIR; HEPATITIS B VACCINE; HYDROXYCHLOROQUINE; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 7; LOPINAVIR PLUS RITONAVIR; MARAVIROC; MESALAZINE; METHOTREXATE; PLACEBO; PRAVASTATIN; PREBIOTIC AGENT; PROBIOTIC AGENT; RALTEGRAVIR; RIFAXIMIN; ROSUVASTATIN; SALAZOSULFAPYRIDINE; SEVELAMER; SIMVASTATIN; TENOFOVIR; VALACICLOVIR; VALGANCICLOVIR;

ARTICLE; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC IMMUNE ACTIVATION; COMBINATION CHEMOTHERAPY; COMORBIDITY; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DOWN REGULATION; DRUG EFFECT; DRUG EXCRETION; DRUG MEGADOSE; EFFECTOR CELL; ENTERITIS; EPSTEIN BARR VIRUS INFECTION; HEPATITIS B; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOMODULATION; INTESTINE FLORA; INTESTINE LYMPHATIC TISSUE; LOW DRUG DOSE; MAJOR HISTOCOMPATIBILITY COMPLEX; METABOLIC SYNDROME X; MICROBIAL ACTIVITY; MICROBIAL TRANSLOCATION; MIXED INFECTION; NONHODGKIN LYMPHOMA; NONHUMAN; OBESITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RHEUMATOID ARTHRITIS; SENESCENCE; SEROPREVALENCE; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; T LYMPHOCYTE ACTIVATION; TH17 CELL; TREATMENT DURATION; VIREMIA; VIRUS HEPATITIS; VIRUS LOAD; VIRUS REPLICATION;

ANTI-RETROVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; COINFECTION; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; IMMUNITY, INNATE; LYMPHOCYTE ACTIVATION; VIRUS REPLICATION;

EID: 84873739567     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-012-0147-3     Document Type: Article

References (100)

1. • French MA, King MS, Tschampa JM, da Silva BA, Landay AL. Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells. J Infect Dis. 2009;200:1212-5. This study demonstrated the inability of cART to normalize immune activation markers in HIV-infected patients.
2. • Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin infect Dis. 2011;53(11):1120-6. By showing that non-infectious co-morbidities develop about 15 years earlier despite cART in HIV-infected patients, this study stimulated increased interest in addressing HIV infection as an independent risk factor for a variety of non-AIDS conditions.
3. Antiretroviral Therapy Collaboration. Causes of death in HIV-1-infected individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Clin Infect Dis. 2010;50:1387-96.
4. Cecchinato V, Trindade CJ, Laurence A, et al. Altered balance between Th17 and Th1 cells at mucosal sites predicts AIDS progression in simian immunodeficiency virus-infected macaques. Mucosal Immunol. 2008;1:279-88. (Pubitemid 351850534)
5. Brenchley JM, Paiardini M, Knox KS, et al. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood. 2008;112:2826-35.
6. Gori A, Tincati C, Rizzardini G, et al. Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immnunodeficiency virus pathogenesis. J Clin Microbiol. 2008;46:757-8. (Pubitemid 351231331)
7. Epple HJ, Schneider T, Troeger H, et al. Impairment of the intestinal barrier is evident in untreated but absent in suppressively treated HIV-infected patients. Gut. 2009;58(2):220-7.
8. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365-71. (Pubitemid 44924494)
9. Guadalupe M, Reay E, Sankaran S, et al. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol. 2003;77:11708-17. (Pubitemid 37271669)
10. •• Wallet MA, Rodriguez CA, Yin L, et al. Microbial translocation induces persistent macrophages activation unrelated to HIV-1 levels or T-cell activation following therapy. AIDS. 2010;24:1281-90. This study showed the association between microbial translocation and immune activation despite cART.
11. Rajasuriar R, Booth D, Solomon A, et al. Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor alpha and microbial translocation. J Infect Dis. 2010;202:1254-64.
12. • Sandler NG, Douek DC. Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol. 2012;10:655-66. This is a comprehensive overview of microbial translocation as it relates to HIV.
13. Jiang W, Lederman MM, Hunt P, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis. 2009;199:1177-85.
14. •• Lederman MM, Calabrese L, Funderburg NT, et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis. 2011;204(8):1217-26. In this study, poor immune response during cART was shown to be connected to immune activation in ways that may provide opportunities for therapeutic intervention.
15. Descombe JJ, Dubourg D, Picard M, Palazzini E. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Pharmacol Res. 1994;14(2):51-6. (Pubitemid 24289441)
16. Debbia EA, Maioli E, Roveta S, et al. Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations. J Chemother. 2008;20:186-94. (Pubitemid 351797058)
17. Mencarelli A, Renga B, Palladino G, Claudia D, et al. Inhibition of NF-kB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells. Eur J Pharmacol. 2011;668(1-2):317-24.
18. Vlachogiannakos J, Saveriadis AS, Viazis N, et al. Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Aliment Pharmacol Ther. 2009;29:992-9.
19. Kalambokis GN, Tsianos EV. Rifaximin reduces endotoxemia and improves liver function and disease severity in patients with decompensated cirrhosis. Hepatology. 2012;55(2):655-6.
20. Pandrea I, Haret-Richter G, Ma D, et al. Administration of rifaximin and sulfasalazine during acute SIV infection decreases microbial translocation and coagulation marker levels and significantly impacts viral replication. Abstract 162. In: Program and abstracts of the 19th Conference on Retroviruses and Opportunistic Infections. March 5-12. Seattle WA; 2012.
21. Sun PP, Perianayagam MC and Jaber BL. Endotoxin-binding affinity of sevelamer: a potential novel anti-inflammatory mechanism. Kidney Int Suppl. 2009;S20-5.
22. Stinghen AE, Goncalves SM, Bucharles S, et al. Sevelamer decreases systemic inflammation in parallel to a reduction in endotoxemia. Blood Purif. 2010;29:352-6.
23. Ellis CL, Ma ZM, Mann SK, et al. Molecular characterization of stool microbiota in HIV-infected subjects by panbacterial and order-level 16S ribosomal DNA (rDNA) quantification and correlations with immune activation. J Acquir Immune Defic Syndr. 2011;57(5):363-70.
24. Reid G, Sanders ME, Gaskins HR, et al. New scientific paradigms for probiotics and prebiotics. J Clin Gastroenterol. 2003;37(2):105-18. (Pubitemid 36875569)
25. Cunningham-Rundles S, Ahrne S, Johann-Liang R, et al. Effect of probiotic bacteria on microbial host defense, growth and immune function in human immunodeficiency virus type-1 infection. Nutrients. 2011;3(12):1042-70.
26. • Gori A, Rizzardini G, Van'tLand B, et al. Specific prebiotics modulate gut microbiota and immune activation in HAART-naïve HIV-infected adults: results of the "COPA" pilot randomized trial. Mucosal Immunol. 2011;4(5):554-63. This pilot trial provides preliminary evidence that nutritional supplementation with prebiotics may be a clinical intervention to modulate chronic immune activation.
27. •• Levy Y, Sereti I, Tambussi G, et al. Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clin Infect Dis. 2012;55:291-300. IL-7 was shown as a potential intervention to improve T cell reconstitution in HIV-infected patient.
28. Sereti I, Estes J, Thompson W, et al. Gut mucosa T lymphocyte restoration in chronically HIV + patients treated with recombinant interleukin-7. Abstract 94. In Program and Abstract of the Conference on Retroviruses and Opportunistic Infection 2012. Seattle WA.
29. • Micci L, Cervasi B, Ende ZS, et al. Paucity of interleukin (IL-21) producing CD4+ T-cells is associated with Th17 cell depletion in SIV-infection of rhesus macaques. Blood 2012 Sep 18. E pub ahead of print. Depletion of CD4 + IL21+ T cells in blood and rectal mucosa was shown in a macaque model to correlate with loss TH17 cells.
30. Chun T, Murray D, Justement JS, Hallahan CW, Moir S, Kovacs C, Fauci AS. Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J Infect Dis. 2011;204:135-8.
31. Kramer VG, Schader SM, Oliveira M, et al. Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load. Antimicrob Agents Chemother. 2012;56:4154-60.
32. Buzon MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med. 2010;16:460-5.
33. Libre JM, Buzon MJ, Massanella M, et al. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. Antivir Ther. 2012;17:355-64.
34. Yukl SA, Shergill AK, McQuaid K, et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS. 2010;24:2451-60.
35. Gandhi RT, Coombs RW, Chan ES, et al. No effect of raltegravir intensification on viral replication markers in the blood of HIV-1 infected patients receiving antiretroviral therapy. JAIDS. 2012;59:229-35.
36. Dahl V, Lee E, Peterson J, et al. Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy. J Infect Dis. 2011;204:1936-45.
37. Byakwaga H, Kelly M, Purcell DF, et al. Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial. J Infect Dis. 2011;204:1532-40.
38. McMahon D, Jones J, Markovitz DM, et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis. 2010;50(6):912-9.
39. Dinoso JB, Kim SY, Wiegand AM, et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 2009;106(23):9403-8.
40. Archin NM, Cheema M, Parker D, et al. Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS One. 2010;5:e9390.
41. Chege D, Kovacs C, la Porte C, et al. Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial. AIDS. 2012;26:167-74.
42. Liu Z, Cumberland WG, Hultin LE, et al. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers or combinations of HLA DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:83-92.
43. • Modjarrad K, Vermund SH. Effect of treating co-infections on HIV-1 viral load: a systematic review. Lancet Infect Dis. 2010;10:455-63. This review demonstrated that co-infections contribute significantly to immune activation in HIV infection and makes a case for treatment/suppression of culprit pathogens.
44. Roxby AC, Liu AY, Drake AL, et al. T Cell activation in HIV-1/Herpes Simplex Virus-2-coinfected Kenyan women receiving valacyclovir. AIDS Res Human Retroviruses 2012 Sep 4. E pub ahead of print.
45. Patel P, Bush T, Desai S, et al. Prevalence and risk factors associated with herpes simplex virus-2 infection in a contemporary cohort of HIV-infected persons in the United States. Sex Trams Dis. 2012;39(2):254-60.
46. Hechter RC, Budoff M, Hodis HN, et al. Herpes simplx virus type 2 (HSV-2) as a coronary atherosclerosis risk factor in HIV-infected men: multicenter AIDS cohort study. Atherosclerosis. 2012;223(2):433-6.
47. Sheth PM, Sunderji S, Shin LY, et al. Coinfection with herpes simplex virus type 2 is associated with reduced HIV-specific T cell responses and systemic immune activation. J Infect Dis. 2008;197:1394-401. (Pubitemid 351706463)
48. Stein JH, Hsue PY. Inflammation, immune activation, and CVD risk in individuals with HIV infection. JAMA. 2012;308(4):405-6.
49. Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med. 2010;20(4):202-13.
50. Van de Berg PJ, Heutinck KM, Raabe R, et al. Human cytomegalovirus induces systemic immune activation characterized by a type 1 cytokine signature. J Infect Dis. 2010;202(5):690-9.
51. Pawelec G, Derhovanessian E. Role of CMV in immune senescence. Virus Res. 2011;157(2):175-9.
52. Parrinello CM, Sinclair E, Landay AL, et al. Cytomegalovirus immunoglobulin G antibody is associated with subclinical carotid artery disease among HIV-infected women. J Infect Dis. 2012;205:1788-96.
53. Naeger DM, Martin JN, Sinclair E, et al. Cytomegolavirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease. PLoS One. 2010;5(1):e8886.
54. Hsue PY, Hunt PW, Sinclair E, et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T -cell response. AIS. 2006;20(18):2275-83. (Pubitemid 44789529)
55. •• Hunt PW, Martin JN, Sinclair E, et al. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis. 2011;203:1474-83. This study provides randomized clinical trial evidence that suppression of CMV replication can reduce immune activation in HIV-infected patients who have relatively poor CD4 count response to cART.
56. • Petrara MR, Cattelan AM, Zanchetta M, et al. Epstein-Barr virus load and immune activation in human immunodeficiency virus type 1-infected patients. J Clin Virol. 2012;53:195-200. Highlights the potential contribution of EBV, a common herpesvirus, to immune activation. This is important because EBV infection is rarely considered or adjusted for in clinical trials.
57. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;34(18):556-62. (Pubitemid 29384163)
58. Sajadi MM, Pulijuala R, Redfield RR, Talwani R. Chronic immune activation and decreased CD4 cell counts associated with hepatitis C infection in HIV-1 natural viral supressors. AIDS. 2012;26:1879-84.
59. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-5.
60. Krishnan S, Schouten JT, Atkinson B, et al. Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naïve HIV-infected individuals. J Acquir Immune Defic Syndr. 2012 E pub July 23, 2012.
61. Sell H, Habich C, Eckel J. Adaptive immunity in obesity and insulin resistance. Nat Rev Endocrinol. 201;doi: 10.1038/nrendo.2012.114.
62. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005;4:977-87.
63. Kuipers HF, van den Elsen PJ. Immunomodulation by statins: inhibition of cholesterol vs. isoprenoid biosynthesis. Biomed Pharmacother. 2007;61:400-7. (Pubitemid 47239347)
64. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6:1399-402. (Pubitemid 32001026)
65. Aslangul E, Fellahi S, Assoumou LK, Bastard JP, Capeau J, Costagliola D. High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors. AIDS. 2011;25:1128-31.
66. Calza L, Trapani F, Bartoletti M, et al. Statin therapy decreases serum levels of high-sensitivity C-reactive protein and tumor necrosis factor-alpha in HIV-infected patients treated with ritonavir-boosted protease inhibitors. HIV Clin Trials. 13(3):153-61.
67. Ganesan A, Crum-Cianflone N, Higgins J, et al. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-bind randomized placebo controlled clinical trial. J Infect Dis. 2011;203:756-64.
68. Amet T, Nonaka M, Dewan MZ, et al. Statin-induced inhibition of HIV-1 release from latently infected UI cells reveals a critical role for protein prenylation in HIV-1 replication. Microbes Infect. 2008;10:471-80.
69. Moncunill G, Negredo E, Bosch L, et al. Evaluation of the anti-HIV activity of statins. AIDS. 2005;19:1697-700. (Pubitemid 41502686)
70. Fichtenbaum CJ, Yeh TM, Evans SE, Aberg SA. Improvement in atherogenic lipid profiles in HIV-infected persons participating in ACTG 5087 who were treated with pravastatin, fenofibrate or the combination. J Clin Lipidol. 2010;4:279-87.
71. De Wit S, Delforge M, Necsol CV, Clumeck N. Downregulation of CD38 activation markers by atorvastatin in HIV patients with undetectable viral load. AIDS. 2011;25(10):1332-3.
72. Fehr T, Kalhert C, Fierz W, et al. Statin-induced immunomodulatory effects on human T cells in vivo. Atherosclerosis. 2004;175:83-90. (Pubitemid 38746913)
73. Hürlimann D, Chenevard R, Ruschitzka F, et al. Effects of statins on endothelial function and lipid profile in HIV infected persons receiving protease inhibitor-containing antiretroviral combination therapy: a randomized double blind crossover trial. Heart. 2006;92(1):110-2. (Pubitemid 43021872)
74. Moore RD, Bartlett JG, Gallant JE. Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients. PLoS One. 2011;6(7):e21843.
75. Chao C, Xu L, Abrams DI, et al. HMG-CoA reductase inhibitors (statins) use and risk of non-Hodgkin lymphoma in HIV-positive persons. AIDS. 2011;25(14):1771-7.
76. Chiang G, Sassaroli M, Louise M, Chen H, Stecher VJ, Sperber K. Inhibition of HIV replication by hydroxychloroquine. Clin Ther. 1996;18(6):1080-92. (Pubitemid 27077112)
77. Rayne F, Vendeville A, Bonhoure A, Beaumelle B. The ability of chloroquine to prevent tat-induced cytokine secretion by monocytes is implicated in its in vivo anti-human immunodeficiency virus type 1 activity. J Virol. 2004;78(21):12054-7. (Pubitemid 39390790)
78. Narding MA, Baan E, Pollakis G, Paxton WA. Effect of chloroquine on reducing HIV-1 replication in vitro and the DC-SIGN mediated transfer of virus to CD4 positive T-lymphocytes. Retrovirology. 2007;30(4):6.
79. Vijaykumar TS, Nath A, Chauhan A. Chloroquine mediated molecular tuning of astrocytes for enhanced permissiveness to HIV infection. Virology. 2008;381:1-5.
80. Rutz M, Metzger T, Gellert P, et al. Toll-like receptor 9 binds single-stranded CpG DNA in a sequence- and pH-dependent manner. Eur J Immunl. 2004;34:2541-50. (Pubitemid 39302811)
81. Martison JA, Montoya CJ, Usuga X, et al. Chloroquine modulates HIV-1 induced plasmacytoid dendritic cell alpha interferon: implication for T-cell activation. Antimicrob Agents Chemother. 2010;54(2):871-81.
82. Goldman FD, Gilman AL, Hollenback C, Kato RM, Premack BA, Rawlings DJ. Hydroxychloroquine inhibits calcium signals in T cells. Blood. 2000;95(11):3460-6.
83. Ziegler HK, Unanue ER. Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells. Proc Natl Acad Sci U S A. 1982;79(1):175-8. (Pubitemid 12181509)
84. Murray SM, Down CM, Boulware DR, et al. Reduction in immune activation with chloroquine therapy during chronic HIV infection. J Virol. 2010;84(22):12082-6.
85. Sperber K, Kalb TH, Stecher VJ, et al. Inhibition of human Immunodeficiency virus type 1 by hydroxychloroquine in T cells and monocytes. AIDS Res Hum Retrovir. 1993;9:91-8. (Pubitemid 23055136)
86. Sperber K, Louie M, Kraus T, et al. Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin Ther. 1995;17(4):622-36.
87. •• Paton IN, Goodall RL, Dunn DT, et al. Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy. A randomized trial. JAMA. 2012;308(4):353-61. In the absence of cART, hydroxychloroquine was found to have no beneficial impact and potential safety concerns emerged from this study.
88. Piconi S, Parisotto S, Rizzardini G, et al. Hydroxychlroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood. 2011;118(12):3263-72.
89. Camargo JF, Quinones MP, Mummidi S, et al. CCR5 expression levels influence NFAT translocation, IL-2 production, and subsequent signaling events during T lymphocyte activation. J Immunol. 2009;182:171-82.
90. Rossi R, Lichtner M, De Rosa A, et al. In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells. Clin Exp Immunol. 2011;166:184-90.
91. • Wilkin TJ, Lalama CM, McKinnon J, et al. A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4+ T-cell recovery despite sustained virologic suppression: ACTG A5256. J Infect Dis. 2012;206(4):534-42. This study found that maraviroc lowered markers of immune activation but the results contrasted those of a similar study (reference 90). This underscores the importance of standardizing procedures for sample collection and processing in clinical trials, particularly those that involve cell-based biomarkers.
92. Gutierrez C, Diaz L, Vallejo A, et al. Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected. PLoS One. 2011;6:e27864.
93. Rusconi S, Vitiello P, Adorni F, et al. Maraviroc as intensification for HIV-1-positive immunological non-responders (INRs) despite virological suppression during HAART. J Int AIDS Soc. 2010;13 Suppl 4:044.
94. + T cell recovery during suppressive ART. Abstract 153LB In: Program and abstracts of the 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 27-March 2, 2011.
95. Yilmaz A, Verhofstede C, D'Avolio A, et al. Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy. J Acquir Immune Defic Syndr. 2010;55:590-6.
96. Cutolo M, Sulli A, Pizzorni C, Seriolo B, et al. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis. 2001;60:729-35. (Pubitemid 32685871)
97. Chan ESL, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res. 2002;4:266-473. (Pubitemid 34716307)
98. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002;359:1173-7. (Pubitemid 34304256)
99. Hochberg MC, Johnston SS, John AK. The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006. Curr Med Res Opin. 2008;24:469-80. (Pubitemid 351294396)
100. Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol. 2011;108(9):1362-70.